Lakefront Biotherapeutics (GLPGF) Assets Average (2015 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Assets Average for 11 consecutive years, with $4.0 billion the latest figure, recorded in Q1 2026.

• On a quarterly basis, Assets Average fell 8.51% year-over-year to $4.0 billion in Q1 2026; TTM through Mar 2026 was $4.0 billion, a 8.51% decrease from a year earlier, with the FY2025 full-year figure at $4.2 billion, down 9.16% from the prior year.
• Assets Average was $4.0 billion for Q1 2026 at Lakefront Biotherapeutics, down from $4.0 billion in the prior quarter.
• Over five years, Assets Average peaked at $5.8 billion in Q1 2022 and troughed at $4.0 billion in Q1 2026.
• A 5-year average of $4.6 billion and a median of $4.4 billion in 2025 frame the typical range for Assets Average.
• Across the five-year window, Assets Average retreated 15.97% in 2023 and decreased 3.83% in 2024, its largest moves.
• Over 5 years, Assets Average stood at $5.8 billion in 2022, then retreated by 18.27% to $4.8 billion in 2023, then slipped by 5.59% to $4.5 billion in 2024, then decreased by 10.34% to $4.0 billion in 2025, then retreated by 1.95% to $4.0 billion in 2026.
• The last three Assets Average figures came in at $4.0 billion (Q1 2026), $4.0 billion (Q4 2025), and $4.2 billion (Q3 2025), per Business Quant data.